Print
Email
Print Edition Stories
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Epizyme Inc., a Cambridge-based biotechnology company, has closed a $32 million series B funding round, led by new investor Bay City Capital. The company also added two additional new investors to its roster, Amgen Ventures and Astellas Venture. Existing investors MPM Capital and Kleiner Perkins Caufield and Byers (KPCB), also participated in the round.
As part of the funding round, Carl Goldfischer, a Bay City Capital investment partner and managing director, will join Epizyme’s board of directors.
MPM and Kleiner Perkins co-led the company’s first round of funding, which pulled in $14 million in February 2008.
The company focuses on therapeutics that inhibit those enzymes that are potentially responsible for certain cancers, inflammatory conditions, metabolic disorders and neurodegenerative diseases.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
